Gilead Sciences Noncontrolling interests in subsidiaries remained flat by 0.0% to -$84.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from -$84.00M to -$84.00M. Over 5 years (FY 2020 to FY 2025), Noncontrolling interests in subsidiaries shows a downward trend with a 34.6% CAGR.
Changes reflect the acquisition or divestiture of minority stakes in subsidiaries or the relative profitability of those specific entities.
This represents the portion of equity in a subsidiary that is not attributable, directly or indirectly, to the parent co...
Common in companies with complex organizational structures and joint ventures.
other_minority_interest| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $7.00M | $1.00M | -$5.00M | -$12.00M | -$21.00M | -$24.00M | -$31.00M | -$58.00M | -$64.00M | -$72.00M | -$84.00M | -$84.00M | -$84.00M | -$84.00M | -$84.00M | -$84.00M | -$84.00M | -$84.00M | -$84.00M | -$84.00M |
| QoQ Change | — | -85.7% | -600.0% | -140.0% | -75.0% | -14.3% | -29.2% | -87.1% | -10.3% | -12.5% | -16.7% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| YoY Change | — | — | — | — | -400.0% | <-999% | -520.0% | -383.3% | -204.8% | -200.0% | -171.0% | -44.8% | -31.3% | -16.7% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |